United Therapeutics ($UTHR) Insider Trading & Smart Money Activity
United Therapeutics Corporation ($UTHR) has 62 insider trades and 3 analyst ratings on file. In the last 12 months on the open market, no insider bought and 7 insiders sold ($169.74M), net -$169.74M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 7
- Net insider $ (12 mo)
- -$169.74M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 3
UTHR insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 11 · $56.57M | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 11 · $46.79M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 13 · $66.37M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All UTHR insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Martine A RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.19M | -2.84% | SEC | Read | ||||
| Insider | Paul A MahonEVP & GENERAL COUNSEL | Sell (Open-market sale) 10b5-1 | 8.30K sh | $4.52M | -15.52% | SEC | Read | ||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.13M | Read | ||||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.18M | Read | ||||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.23M | Read | ||||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.18M | -2.9% | Read | |||||
| Analyst | RBC Capital | Reiterates to Outperform | PT $708 | +1.6% | — | ||||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.08M | +1.6% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.22M | -0.9% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.12M | +0.3% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.15M | +2.6% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.22M | +1.4% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.48M | -6.8% | — | |||||
| Insider | Mahon Paul AEVP & GENERAL COUNSEL | Sell (Open-market sale) 10b5-1 | 8.30K sh | $4.69M | -6.8% | — | |||||
| Analyst | BTIG | Raises to Buy | PT $728 | -6.8% | — | ||||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 1.92K sh | $1.06M | +0.6% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.54M | +12.5% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.57M | +10.5% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.52M | +13.9% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.50M | +21.0% | — | |||||
| Analyst | Goldman Sachs | Reiterates to Sell | PT $321 | +21.0% | — | ||||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.67M | +10.7% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.70M | -3.2% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.70M | -1.5% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.70M | -3.9% | — | |||||
| Insider | Rothblatt Martine AChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $4.71M | -5.0% | — | |||||
| Insider | Mahon Paul AEVP & GENERAL COUNSEL | Sell (Open-market sale) 10b5-1 | 8.30K sh | $4.13M | -5.0% | — | |||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.19M | +0.4% | -3.7% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.29M | +0.4% | -3.7% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Option exercise) | 9.50K sh | +0.8% | -2.7% | Read | |||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.29M | +0.8% | -2.7% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Option exercise) | 9.50K sh | +2.3% | -2.8% | — | |||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.29M | +2.3% | -2.8% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.21M | -0.5% | -3.9% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.29M | -0.5% | -3.9% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.17M | -0.5% | -2.7% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.29M | -0.5% | -2.7% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Option exercise) | 9.50K sh | +1.2% | -2.1% | Read | |||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.32M | +1.2% | -2.1% | Read | ||||
| Insider | James EdgemondCFO AND TREASURER | Sell (Open-market sale) 10b5-1 | 8.75K sh | $4.71M | +1.2% | -2.1% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Buy (Option exercise) | 8.75K sh | $1.28M | +1.2% | -2.1% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.13M | +1.3% | -1.4% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | +1.3% | -1.4% | — | ||||
| Insider | Paul MahonEVP & GENERAL COUNSEL | Sell (Open-market sale) 10b5-1 | 8.30K sh | $4.49M | +1.3% | -1.4% | — | ||||
| Insider | Paul MahonEVP & GENERAL COUNSEL | Buy (Option exercise) | 8.30K sh | $1.21M | +1.3% | -1.4% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Sell (Option exercise) | 10K sh | +1.3% | -1.4% | — | |||||
| Insider | James EdgemondCFO AND TREASURER | Buy (Option exercise) | 10K sh | $1.46M | +1.3% | -1.4% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.25M | -0.3% | -2.9% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | -0.3% | -2.9% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.22M | -0.7% | -3.5% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | -0.7% | -3.5% | Read | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Option exercise) | 9.50K sh | -2.1% | -3.2% | — | |||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | -2.1% | -3.2% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Sell (Option exercise) | 10K sh | -2.1% | -3.2% | — | |||||
| Insider | James EdgemondCFO AND TREASURER | Buy (Option exercise) | 10K sh | $1.18M | -2.1% | -3.2% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Option exercise) | 9.50K sh | -1.4% | -1.9% | — | |||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | -1.4% | -1.9% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Open-market sale) 10b5-1 | 9.50K sh | $5.22M | -1.6% | -1.8% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Sell (Option exercise) | 9.50K sh | -1.6% | -1.8% | — | |||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | -1.6% | -1.8% | — | ||||
| Insider | Martine RothblattChairperson & CEO | Buy (Option exercise) | 9.50K sh | $1.39M | -1.6% | -1.8% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Sell (Open-market sale) 10b5-1 | 10K sh | $5.49M | -1.6% | -1.8% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Sell (Open-market sale) 10b5-1 | 10K sh | $5.49M | -1.6% | -1.8% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Buy (Option exercise) | 10K sh | $1.18M | -1.6% | -1.8% | — | ||||
| Insider | James EdgemondCFO AND TREASURER | Buy (Option exercise) | 10K sh | $1.18M | -1.6% | -1.8% | — |
1W / 1M / 6M = how UTHR moved from the trade or filing date.
Insider trading in UTHR: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Martine A Rothblatt | Chairperson & CEO | 1 | -$5.19M | 324.44K | Oct 15, 2026 |
| Paul A Mahon | EVP & GENERAL COUNSEL | 1 | -$4.52M | 45.17K | Oct 15, 2026 |
| Rothblatt Martine A | Chairperson & CEO | 20 | -$94.63M | Oct 14, 2026 | |
| Mahon Paul A | EVP & GENERAL COUNSEL | 2 | -$8.82M | Oct 1, 2026 | |
| Martine Rothblatt | Chairperson & CEO | 26 | -$36.39M | Jun 29, 2026 | |
| James Edgemond | CFO AND TREASURER | 10 | -$15.69M | Jun 22, 2026 | |
| Paul Mahon | EVP & GENERAL COUNSEL | 2 | -$4.49M | Jun 18, 2026 |
Analyst ratings on UTHR
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| RBC Capital | Reiterates | Outperform | $677 → $708 | +1.6% | — | |||
| BTIG | Raises | Buy | $728 | -6.8% | — | |||
| Goldman Sachs | Reiterates | Sell | $321 | +21.0% | — |
Frequently asked questions
Are UTHR insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 7 insiders made 35 open-market sales worth $169.74M, a net -$169.74M.
What is the latest insider trade in UTHR?
Martine A Rothblatt, Chairperson & CEO filed a sell (open-market sale) of 9.50K sh worth $5.19M on Oct 15, 2026.
Other drug manufacturers - specialty & generic stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.